Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD

Macular Degeneration Clinical Trial

Official title:

A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02543229
• Other study ID #: OPT-302-1001
• Status: Completed
• Phase: Phase 1
• First received: August 25, 2015
• Last updated: November 2, 2017
• Start date: July 2015
• Est. completion date: September 2017

Study information

• Verified date: November 2017
• Source: Opthea Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis™ in patients with wet age related macular degeneration (AMD). This study will be conducted in two parts: Part 1 will comprise an open label, sequential dose escalation and Part 2 a randomized dose expansion.

OPT-302 is a soluble form of VEGFR-3 comprising the extracellular domains 1-3 of human vascular endothelial growth factor receptor (VEGFR)-3 and the Fc fragment of human IgG1. It functions by binding and neutralizing the activity of vascular endothelial growth factor (VEGF)-C and VEGF-D on endogenous VEGFR-2 and VEGFR-3.

VEGF-C and VEGF-D promote blood vessel development (angiogenesis) by binding and activating VEGFR-2 and VEGFR-3. VEGF-C is also a potent inducer of vascular permeability or leakage. Angiogenesis and vascular leakage are key hallmarks of wet AMD. Approved therapies for wet AMD include Eylea™ and Lucentis™ which block the activity of VEGF-A, but not VEGF-C or VEGF-D which are alternate members of the same family of molecules.

VEGF-C and VEGF-D can stimulate blood vessel growth and leakage through the same pathway as VEGF-A (via VEGFR-2), as well as through pathways that are independent of VEGF-A (via VEGFR-3). Published studies have also indicated that VEGF-C and VEGF-D play an important role in mediating resistance to therapies that block VEGF-A such as Lucentis™ and Eylea™.

Combination therapy with OPT-302 an anti-VEGF-A agent provides a more complete blockade of the VEGF family. This strategy targets functional redundancy in the VEGF pathway and mechanisms of 'resistance' or sub-response to VEGF-A inhibition.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: September 2017
• Est. primary completion date: February 7, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Able and willing to provide written informed consent

• Age = 50 years of either gender

• Active CNV lesions secondary to AMD (i.e., subretinal or intraretinal fluid on SD-OCT and / or leakage on fluorescein angiography)

• Either no previous treatment in the study eye with IVT anti-VEGF-A therapy (treatment naïve) or prior IVT anti-VEGF-A therapy (previously treated) with sub-optimal response to treatment and the need for additional treatment

• Best corrected visual acuity in the study eye, using ETDRS testing, of 20/320 or better (Snellen equivalent) in Part 1 (dose escalation) and between 20/40 and 20/320 (Snellen equivalent), inclusive, in Part 2 (dose expansion).

• Women of child bearing potential and male subjects with female partners of child bearing potential must be practicing effective contraception during the trial and for at least 3 months following the last dose of study medication

Exclusion Criteria:

• Previous or concurrent use of systemic anti-VEGF-A agents

• Most recent IVT injection of bevacizumab or ranibizumab <28 days prior to screening or aflibercept <42 days prior to screening

• Previous treatment with photodynamic therapy, thermal laser or external beam radiation in the study eye

• Concurrent treatment in either eye for any ocular condition with an investigational drug or device that has not received regulatory approval

• Anatomic damage to the center of the fovea including fibrosis and scarring making up >50% of total lesion area including the CNV in the study eye

• Geographic atrophy involving the center of the fovea in the study eye

• History or presence of a retinal pigment epithelial tear

• Presence of polypoidal choroidal vasculopathy (if in the opinion of the investigator, anti-VEGF treatment would not be of benefit) or retinal angiomatous proliferation

• Active or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye

• History of rhegmatogenous retinal detachment or macular hole in the study eye

• History of vitrectomy

• Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye

• History of vitreous hemorrhage within 4 weeks prior to screening in the study eye

• History of major ocular surgery within prior 6 months or anticipated within next 3 months following dosing on day 1

• Uncontrolled glaucoma in the study eye (defined as intraocular pressure of >25 mmHg despite treatment with maximal medical therapy)

• Uncontrolled hypertension =180 mmHg systolic or =110 mmHg diastolic at baseline

• Uncontrolled diabetes mellitus (Disease must be controlled with hemoglobin A1c (HgbA1c) < 9.0%)

• Clinical evidence of diabetic retinopathies, diabetic macular edema or any other vascular disease affecting the retina, other than AMD, in either eye that, in the opinion of the investigator, would be likely to limit improvement in the macular anatomy and/or function

• Pregnancy or lactation

Related Conditions & MeSH terms

• Eye Diseases
• Macular Degeneration
• Neovascularization, Pathologic
• Retinal Degeneration
• Retinal Diseases

Intervention

Drug:
• OPT-302
OPT-302 will be administered by intravitreal injection once every month for 3 months
• Lucentis™
Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months

Locations

Country	Name	City	State
United States	Opthea Investigative Site	Abilene	Texas
United States	Opthea Investigative Site	Beverly Hills	California
United States	Opthea Investigative Site	Bloomfield	New Jersey
United States	Opthea Investigative Site	Charlotte	North Carolina
United States	Opthea Investigative Site	Cleveland	Ohio
United States	Opthea Investigative Site	Fort Myers	Florida
United States	Opthea Investigative Site	Pensacola	Florida
United States	Opthea Investigative Site	Phoenix	Arizona
United States	Opthea Investigative Site	Sacramento	California
United States	Opthea Investigative Site	Santa Maria	California
United States	Opthea Investigative Site	West Columbia	South Carolina
United States	Opthea Investigative Site	Wichita	Kansas
United States	Opthea Investigative Site	Willow Park	Texas
United States	Opthea Investigative Site	Winter Haven	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Opthea Limited

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory: Changes in the systemic blood levels of angiogenesis-related biomarkers	Change in systemic blood levels of angiogenesis-related biomarkers including, but not limited to: Vascular Endothelial Growth Factor A (VEGF-A), VEGF-C, VEGF-D, soluble VEGFR-2 and soluble VEGFR-3.	3 months
Primary	Safety (Adverse Events)	Subject incidences of ophthalmic and systemic Adverse Events during study and follow-up period	Up to 1 month after the last dose
Secondary	Mean change in Best Corrected Visual Acuity (BCVA) from baseline	Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline	6 months
Secondary	Mean change in central retinal thickness from baseline	Changes in intra- or sub-retinal fluid measured as mean change in central retinal thickness or macula volume by Spectral Domain Optical Coherence Tomography (SD-OCT)	6 months
Secondary	Mean change in Choroidal Neovascularization (CNV) lesion area from baseline	Change in CNV size according to fluorescein angiogram	6 months
Secondary	Mean number of retreatment injections of anti-VEGF-A therapy during long term follow-up (week 12 to 24)		3 months
Secondary	Need for 'rescue therapy' with ranibizumab in subjects receiving OPT-302 monotherapy		3 months
Secondary	Assess the Pharmacokinetic profile of OPT-302 alone and in combination with ranibizumab following intravitreal administration	Mean systemic OPT-302 Concentration-Time profile	Up to 28 days post-dose
Secondary	Anti-OPT-302 antibody formation	Incidence of anti-OPT-302 antibody formation	Pre-dose and up to 3 months post-dose